Valuation Thiogenesis Therapeutics, Corp. OTC Markets
Stocks
TTIPF
CA88410L1022
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
09:30:19 2026-08-07 EDT
|
5-day change | 1st Jan Change | ||
| 0.4200 USD | +7.69% |
|
0.00% | -28.01% |
Company Valuation: Thiogenesis Therapeutics, Corp.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 22.54 | 33.43 | 27.61 | 33.69 |
| Change | - | 48.3% | -17.4% | 22.03% |
| Enterprise Value (EV) 1 | 16.34 | 26.35 | 23.76 | 32.08 |
| Change | - | 61.23% | -9.83% | 34.99% |
| P/E | -3.74x | -5.8x | -8.65x | -4.25x |
| PBR | 3.77x | 6.04x | 8.06x | 58.7x |
| PEG | -0x | 0.3x | 0.2x | -0x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / EBIT | -8.14x | -5.06x | -6.64x | -4.34x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 3 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 3 | -0.1552 | -0.1294 | -0.0693 | -0.1528 |
| Distribution rate | - | - | - | - |
| Net sales | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -2.009 | -5.206 | -3.579 | -7.395 |
| Net income 1 | -3.924 | -5.063 | -3.146 | -7.426 |
| Net Debt 1 | -6.196 | -7.076 | -3.848 | -1.616 |
| Reference price 3 | 0.5800 | 0.7500 | 0.6000 | 0.6500 |
| Nbr of stocks (in thousands) | 38,862 | 44,571 | 46,017 | 51,836 |
| Announcement Date | 4/28/23 | 4/29/24 | 4/25/25 | 4/30/26 |
1CAD in Million2USD in Million3CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.01x | 6.07x | 18.05x | 0.94% | 50.5B | ||
| -22.28x | 305.61x | -22.68x | -.--% | 46.01B | ||
| 49.37x | 5.74x | 31.39x | -.--% | 42.85B | ||
| 32.1x | 3.15x | 13.59x | -.--% | 41.03B | ||
| 29.53x | 8.51x | 21.44x | 0.39% | 32.02B | ||
| 34.59x | 5.67x | 25.77x | -.--% | 16.98B | ||
| 23.56x | 2.06x | 8.91x | 1.14% | 14.3B | ||
| 77.58x | 4.08x | 15.82x | -.--% | 13.84B | ||
| Average | 32.31x | 42.61x | 14.04x | 0.31% | 32.19B | |
| Weighted average by Cap. | 27.45x | 59.01x | 12.58x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TTI Stock
- TTIPF Stock
- Valuation Thiogenesis Therapeutics, Corp.
Select your edition
All financial news and data tailored to specific country editions
















